Lurasidone and fluoxetine reduce novelty-induced hypophagia and NMDA receptor subunit and PSD-95 expression in mouse brain

European Neuropsychopharmacology

Volumn 25, Issue 10, 2015, Pages 1714-1722

  Stan, Tiberiu Loredan ^a   Sousa, Vasco Cabral ^a   Zhang, Xiaoqun ^a   Ono, Michiko ^b   Svenningsson, Per ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Depression; Glutamate; Hippocampus; Prefrontal cortex; PSD 95

Indexed keywords

FLUOXETINE; LURASIDONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; POSTSYNAPTIC DENSITY PROTEIN 95; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DLGH4 PROTEIN, MOUSE; GPRIN1 PROTEIN, MOUSE; GUANYLATE KINASE; MEMBRANE PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE PROTEIN; NEUROLEPTIC AGENT; NR2A NMDA RECEPTOR; NR2B NMDA RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; GENE EXPRESSION; HIPPOCAMPUS; HYPOPHAGIA; LATENT PERIOD; LOCOMOTION; LONG TERM CARE; MALE; MOUSE; NESTING; NONHUMAN; NOVELTY INDUCED HYPOPHAGIA; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT DURATION; WEIGHT GAIN; WESTERN BLOTTING; ANIMAL; ANXIETY; C57BL MOUSE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; DRUG THERAPY; FEEDING BEHAVIOR; METABOLISM; MOTOR ACTIVITY; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; RANDOMIZATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEEDING BEHAVIOR; FLUOXETINE; GUANYLATE KINASE; HIPPOCAMPUS; LURASIDONE HYDROCHLORIDE; MALE; MEMBRANE PROTEINS; MICE, INBRED C57BL; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; PREFRONTAL CORTEX; RANDOM ALLOCATION; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84943349021     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.07.007     Document Type: Article

References (39)

1. Aoki C., Miko I., Oviedo H., Mikeladze-Dvali T., Alexandre L., Sweeney N., Bredt D.S. Electron microscopic immunocytochemical detection of PSD-95, PSD-93, SAP-102, and SAP-97 at postsynaptic, presynaptic, and nonsynaptic sites of adult and neonatal rat visual cortex. Synapse 2001, 40:239-257.
2. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F., Kavalali E.T., Monteggia L.M. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95.
3. Carta M.G., Moro M.F., Nardi A.E., Calabrese J.R. Potential use of lurasidone for the treatment of bipolar psychosis. Expert Opin. Investig. Drugs 2015, 24:575-584.
4. Cates L.N., Roberts A.J., Huitron-Resendiz S., Hedlund P.B. Effects of lurasidone in behavioral models of depression. Role of the 5-HT(7) receptor subtype. Neuropharmacology 2013, 70:211-217.
5. Citrome L., Cucchiaro J., Sarma K., Phillips D., Silva R., Tsuchiya S., Loebel A. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol 2012, 27:165-176.
6. Dulawa S.C., Holick K.A., Gundersen B., Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004, 29:1321-1330.
7. Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012, 338:68-72.
8. Eriksson T.M., Alvarsson A., Stan T.L., Zhang X., Hascup K.N., Hascup E.R., Kehr J., Gerhardt G.A., Warner-Schmidt J., Arango-Lievano M., Kaplitt M.G., Ogren S.O., Greengard P., Svenningsson P. Bidirectional regulation of emotional memory by 5-HT1B receptors involves hippocampal p11. Mol. Psychiatry 2013, 18:1096-1105.
9. Greene-Schloesser D.M., Van der Zee E.A., Sheppard D.K., Castillo M.R., Gregg K.A., Burrow T., Foltz H., Slater M., Bult-Ito A. Predictive validity of a non-induced mouse model of compulsive-like behavior. Behav. Brain Res. 2011, 221:55-62.
10. Haberzettl R., Bert B., Fink H., Fox M.A. Animal models of the serotonin syndrome: a systematic review. Behav. Brain Res. 2013, 256:328-345.
11. Ishibashi T., Horisawa T., Tokuda K., Ishiyama T., Ogasa M., Tagashira R., Matsumoto K., Nishikawa H., Ueda Y., Toma S., Oki H., Tanno N., Saji I., Ito A., Ohno Y., Nakamura M. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther. 2010, 334:171-181.
12. Ishiyama T., Tokuda K., Ishibashi T., Ito A., Toma S., Ohno Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur. J. Pharmacol. 2007, 572:160-170.
13. Kadkhodaei B., Alvarsson A., Schintu N., Ramskold D., Volakakis N., Joodmardi E., Yoshitake T., Kehr J., Decressac M., Bjorklund A., Sandberg R., Svenningsson P., Perlmann T. Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons. Proc. Natl. Acad. Sci. USA 2013, 110:2360-2365.
14. Kiselycznyk C., Jury N.J., Halladay L.R., Nakazawa K., Mishina M., Sprengel R., Grant S.G., Svenningsson P., Holmes A. NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism. Behav. Brain Res. 2015, 287:89-95.
15. Kiselycznyk C., Svenningsson P., Delpire E., Holmes A. Genetic, pharmacological and lesion analyses reveal a selective role for corticohippocampal GLUN2B in a novel repeated swim stress paradigm. Neuroscience 2011, 193:259-268.
16. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., Li X.Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
17. Loebel A., Cucchiaro J., Silva R., Kroger H., Hsu J., Sarma K., Sachs G. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry 2014, 171:160-168.
18. Loebel A., Cucchiaro J., Silva R., Kroger H., Sarma K., Xu J., Calabrese J.R. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry 2014, 171:169-177.
19. Luoni A., Hulsken S., Cazzaniga G., Racagni G., Homberg J.R., Riva M.A. Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats. Int. J. Neuropsychopharmacol./Off. Sci. J. Coll. Int. Neuropsychopharmacol. 2013, 16:1319-1330.
20. Luoni A., Rocha F.F., Riva M.A. Anatomical specificity in the modulation of activity-regulated genes after acute or chronic lurasidone treatment. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2014, 50:94-101.
21. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., Manji H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 2008, 63:349-352.
22. Meltzer H.Y., Cucchiaro J., Silva R., Ogasa M., Phillips D., Xu J., Kalali A.H., Schweizer E., Pikalov A., Loebel A. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am. J. Psychiatry 2011, 168:957-967.
23. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnashev N., Sakmann B., Seeburg P.H. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 1992, 256:1217-1221.
24. Muller H.K., Wegener G., Liebenberg N., Zarate C.A., Popoli M., Elfving B. Ketamine regulates the presynaptic release machinery in the hippocampus. J. Psychiatr. Res. 2013, 47:892-899.
25. Ogden K.K., Traynelis S.F. New advances in NMDA receptor pharmacology. Trends Pharmacol. Sci. 2011, 32:726-733.
26. Paoletti P., Neyton J. NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol. 2007, 7:39-47.
27. Pehrson A.L., Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr. 2014, 19:121-133.
28. Pittaluga A., Raiteri L., Longordo F., Luccini E., Barbiero V.S., Racagni G., Popoli M., Raiteri M. Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus. Neuropharmacology 2007, 53:27-36.
29. Price J., Cole V., Goodwin G.M. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br. J. Psychiatry: J. Ment. Sci. 2009, 195:211-217.
30. Sanacora G., Gueorguieva R., Epperson C.N., Wu Y.T., Appel M., Rothman D.L., Krystal J.H., Mason G.F. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry 2004, 61:705-713.
31. Sanacora G., Treccani G., Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012, 62:63-77.
32. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 2008, 7:426-437.
33. Skolnick P., Layer R.T., Popik P., Nowak G., Paul I.A., Trullas R. Adaptation of N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996, 29:23-26.
34. Stan T.L., Alvarsson A., Branzell N., Sousa V.C., Svenningsson P. NMDA receptor antagonists ketamine and Ro25-6981 inhibit evoked release of glutamate in vivo in the subiculum. Transl. Psychiatry 2014, 4:e395.
35. Svenningsson P., Lindskog M., Ledent C., Parmentier M., Greengard P., Fredholm B.B., Fisone G. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc. Natl. Acad. Sci. USA 2000, 97:1856-1860.
36. Svenningsson P., Tzavara E.T., Witkin J.M., Fienberg A.A., Nomikos G.G., Greengard P. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc. Natl. Acad. Sci. USA 2002, 99:3182-3187.
37. Yuen E.Y., Li X., Wei J., Horiguchi M., Meltzer H.Y., Yan Z. The novel antipsychotic drug lurasidone enhances N-methyl-d-aspartate receptor-mediated synaptic responses. Mol. Pharmacol. 2012, 81:113-119.
38. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864.
39. Zhang J., Lewis S.M., Kuhlman B., Lee A.L. Supertertiary structure of the MAGUK core from PSD-95. Structure 2013, 21:402-413.